Quarter
Charts

THERAPEUTICSMD, INC.

TXMD

CIK 0000025743 · Quarterly mode · latest period FY2025 (Q4) (ending 2025-12-31) · sourced from SEC EDGAR

At a glance · FY2025 (Q4)

Revenue
$893K
↑+33.9% +$226Kvs FY2024 (Q4)
Operating Income
$796K
↑+40.4% +$229Kvs FY2024 (Q4)
Net Income
$764K
↑+55.6% +$273Kvs FY2024 (Q4)
Gross Profit
$893K
↑+33.9% +$226Kvs FY2024 (Q4)

Quality Score

Quality score

6-dimension fundamental snapshot · latest annual filed values · S&P 500 calibration

Strong
67/100
  • Profitability
    0ROIC -12.8% (10% = solid, 20%+ = moat)
  • Liquidity
    100Current Ratio 3.02 (above 1.5 = solid)
  • Leverage
    100D/E -2.01 (under 0.5 = conservative)
  • Efficiency
    0Asset Turnover 0.08x (1.0+ = capital-efficient)
  • Growth
    100Revenue YoY +33.9% (10% = solid, 25%+ = elite)
  • Margin Trend
    100Op Margin -109.9% · trend +453.2pts (4Q avg vs prior 4Q)

Calibrated to S&P 500 medians. Each sub-score is computed from a single CFA-grade ratio (Profitability = ROIC, Liquidity = Current Ratio, Leverage = D/E, Efficiency = Asset Turnover, Growth = Revenue YoY, Margin Trend = 4Q operating-margin avg vs prior 4Q). Overall = simple mean.

DCF intrinsic value

DCF intrinsic value

two-stage Gordon model

Project TXMD's free cash flow forward, discount back at your hurdle rate, divide by diluted shares. Edit the assumptions to see how sensitive the intrinsic value is.

3%

Trailing 3-yr CAGR was -36.0%

10%

10% is a common all-equity benchmark for US large-caps

2.5%

Should be ≤ long-run GDP growth (~2.5% nominal)

5

5-year explicit projection + perpetuity terminal

Intrinsic value per share
$2.96
Total enterprise IV
$34M
Diluted shares
0.01B
Terminal PV
$24M (70% of total)
Year-5 FCF
$3M
YearProjected FCFDiscounted PV
+1$3M$2M
+2$3M$2M
+3$3M$2M
+4$3M$2M
+5$3M$2M
Terminal$39M$24M

DCF outputs are HIGHLY sensitive to growth + WACC assumptions. A 1pp WACC change can shift IV by 20%+. Use this as a sanity-check vs market price, not a target — and always cross-check the underlying FCF source (EDGAR cashflow statement, latest annual). Margin of safety convention: 30-50% discount to IV before buying.

Capital allocation · trailing 4 quarters

how the company spent its cash
Capex (TTM)
—
investment in PP&E
Stock-based comp (TTM)
$75K
non-cash dilution

Balance sheet · 2025-12-31

latest filed snapshot
Total assets
$38M
everything owned
Total liabilities
$11M
everything owed
Stockholders' equity
$27M
shareholder claim
Net debt
$88M
LT debt minus cash

Recent performance · 62 quarters

Revenue↑+33.9% +$226K
$893K
Net Income↑+125.0% +$761K
$152K
Free Cash Flow↑+2105.9% +$358K
$375K
Operating Margin↑+97.4pts
-109.9%

Drill down

TXMD Sankey

See THERAPEUTICSMD, INC.'s revenue flow into every line item of the income statement and balance sheet — every dollar accounted for, with prior-period comparison.

Open Sankey

TXMD Charts

62 quarters of historical line items — Income, Cash Flow, Balance Sheet, plus margins. Click any chart for the trend dialog.

Open Charts

TXMD Key Metrics

EPS, BVPS, FCF/Share, ROE, ROA, ROIC, D/E, Current Ratio, Quick Ratio, Asset Turnover — 10 CFA-grade fundamentals derived from EDGAR data.

Open Key Metrics